Cargando…

Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing

BACKGROUND: Fluoropyrimidines (fluorouracil [5-FU], capecitabine) and irinotecan are commonly prescribed chemotherapy agents for gastrointestinal (GI) malignancies. Pharmacogenetic (PGx) testing for germline DPYD and UGT1A1 variants associated with reduced enzyme activity holds the potential to iden...

Descripción completa

Detalles Bibliográficos
Autores principales:	Varughese, Lisa A., Bhupathiraju, Madhuri, Hoffecker, Glenda, Terek, Shannon, Harr, Margaret, Hakonarson, Hakon, Cambareri, Christine, Marini, Jessica, Landgraf, Jeffrey, Chen, Jinbo, Kanter, Genevieve, Lau-Min, Kelsey S., Massa, Ryan C., Damjanov, Nevena, Reddy, Nandi J., Oyer, Randall A., Teitelbaum, Ursina R., Tuteja, Sony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295185/ https://www.ncbi.nlm.nih.gov/pubmed/35865463 http://dx.doi.org/10.3389/fonc.2022.859846

Ejemplares similares

97856 Implementation of DPYD and UGT1A1 pharmacogenetic testing to guide chemotherapy dosing
por: Varughese, Lisa A., et al.
Publicado: (2021)

Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation
por: Lau-Min, Kelsey S., et al.
Publicado: (2022)

Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland
por: Begré, Ursina B. M., et al.
Publicado: (2022)

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
por: Wu, Angela, et al.
Publicado: (2023)

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece
por: Ragia, Georgia, et al.
Publicado: (2023)

Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation
por: Bignucolo, A., et al.
Publicado: (2023)

Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population
por: Verma, Shefali S., et al.
Publicado: (2022)

Pharmacogenetics of ugt genes in North African populations
por: Gaibar, M., et al.
Publicado: (2018)

Implementation and clinical benefit of DPYD genotyping in a Danish cancer population
por: Paulsen, N.H., et al.
Publicado: (2023)

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines
por: Lunenburg, Carin A. T. C., et al.
Publicado: (2019)

Multi-site investigation of strategies for the clinical implementation of preemptive pharmacogenetic testing
por: Duarte, Julio D., et al.
Publicado: (2021)

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
por: Loganayagam, A, et al.
Publicado: (2013)

Role of the UGT2B17 deletion in exemestane pharmacogenetics
por: Luo, Shaman, et al.
Publicado: (2017)

The Relationship of UGT2B15 Pharmacogenetics and Lorazepam for Anxiety
por: Ching, Nathan R, et al.
Publicado: (2018)

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real‐World Setting
por: Cavallari, LH, et al.
Publicado: (2017)

Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients
por: Stavraka, Chara, et al.
Publicado: (2019)

Best–worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy
por: Salloum, Ramzi G., et al.
Publicado: (2022)

Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy
por: Tuteja, Sony, et al.
Publicado: (2021)

Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines
por: Pritchard, Daryl, et al.
Publicado: (2022)

Towards the clinical implementation of pharmacogenetics in bipolar disorder
por: Salloum, Naji C, et al.
Publicado: (2014)

Allelic Frequency of DPYD Genetic Variants in Patients With Cancer in Spain: The PhotoDPYD Study
por: Miarons, Marta, et al.
Publicado: (2023)

Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice
por: Saif, Muhammad Wasif, et al.
Publicado: (2020)

Correction to: Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines
Publicado: (2022)

The clinical application of UGT1A1 pharmacogenetic testing: Gene-environment interactions
por: Marques, Sara Correia, et al.
Publicado: (2010)

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1
por: de With, Mirjam, et al.
Publicado: (2023)

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
por: Cremolini, Chiara, et al.
Publicado: (2017)

ATP-Binding Cassette Transporters in the Clinical Implementation of Pharmacogenetics
por: López-Fernández, Luis A.
Publicado: (2018)

Pharmacogenetics to Avoid Adverse Reactions in Cardiology: Ready for Implementation?
por: García-González, Xandra, et al.
Publicado: (2021)

Pharmacogenetics implementation in the clinics: information and guidelines for germline variants
por: Olivera, Gladys, et al.
Publicado: (2019)

Ensuring equity: Pharmacogenetic implementation in rural and tribal communities
por: Leitch, Tianna M., et al.
Publicado: (2022)

A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening
por: Tong, Chi C., et al.
Publicado: (2018)

Implementation of Pharmacogenetics in Primary Care: A Multi-Stakeholder Perspective
por: Rigter, Tessel, et al.
Publicado: (2020)

UGT1A1 (TA)(n) Promoter Genotype: Diagnostic and Population Pharmacogenetic Marker in Serbia
por: Vukovic, M, et al.
Publicado: (2018)

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
por: García-Alfonso, P., et al.
Publicado: (2021)

Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
por: Caudle, Kelly E., et al.
Publicado: (2017)

Cost Effectiveness of Pharmacogenetic Testing for Drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines: A Systematic Review
por: Morris, Sarah A., et al.
Publicado: (2022)

Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation
por: Lerer, Bernard, et al.
Publicado: (2006)

Implementation of Pharmacogenetics to Individualize Treatment Regimens for Children with Acute Lymphoblastic Leukemia
por: Maamari, Dimitri, et al.
Publicado: (2020)

Design and Early Implementation Successes and Challenges of a Pharmacogenetics Consult Clinic
por: Arwood, Meghan J., et al.
Publicado: (2020)

Literature Review Concerning the Challenges of Implementing Pharmacogenetics in Primary Care Practice
por: Omer, Mohamed S
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tko77i2tjo4ho7ogko7udsfejt